131 related articles for article (PubMed ID: 36265539)
1. Dimerization of the C-type lectin-like receptor CD93 promotes its binding to Multimerin-2 in endothelial cells.
Barbera S; Raucci L; Tassone G; Tinti L; Prischi F; Santucci A; Mongiat M; Tosi GM; Galvagni F; Dimberg A; Pozzi C; Orlandini M
Int J Biol Macromol; 2023 Jan; 224():453-464. PubMed ID: 36265539
[TBL] [Abstract][Full Text] [Related]
2. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
3. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.
Tosi GM; Neri G; Barbera S; Mundo L; Parolini B; Lazzi S; Lugano R; Poletto E; Leoncini L; Pertile G; Mongiat M; Dimberg A; Galvagni F; Orlandini M
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):30. PubMed ID: 32697305
[TBL] [Abstract][Full Text] [Related]
4. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.
Barbera S; Nardi F; Elia I; Realini G; Lugano R; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
Cell Commun Signal; 2019 May; 17(1):55. PubMed ID: 31138217
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
[TBL] [Abstract][Full Text] [Related]
6. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
[TBL] [Abstract][Full Text] [Related]
7. The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases.
Barbera S; Lugano R; Pedalina A; Mongiat M; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
Matrix Biol; 2021 May; 99():1-17. PubMed ID: 34062268
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A
Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010
[TBL] [Abstract][Full Text] [Related]
9. CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells.
Barbera S; Raucci L; Lugano R; Tosi GM; Dimberg A; Santucci A; Galvagni F; Orlandini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830297
[TBL] [Abstract][Full Text] [Related]
10. CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.
Nativel B; Ramin-Mangata S; Mevizou R; Figuester A; Andries J; Iwema T; Ikewaki N; Gasque P; Viranaïcken W
Immunology; 2019 Oct; 158(2):85-93. PubMed ID: 31335975
[TBL] [Abstract][Full Text] [Related]
11. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.
Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M
Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865
[TBL] [Abstract][Full Text] [Related]
12. CD93 promotes acute myeloid leukemia development and is a potential therapeutic target.
Jia J; Liu B; Wang D; Wang X; Song L; Ren Y; Guo Z; Ma K; Cui C
Exp Cell Res; 2022 Nov; 420(2):113361. PubMed ID: 36152731
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93.
Cicaloni V; Karmakar M; Frusciante L; Pettini F; Visibelli A; Orlandini M; Galvagni F; Mongiat M; Silk M; Nardi F; Ascher D; Santucci A; Spiga O
Front Bioinform; 2022; 2():891553. PubMed ID: 36353214
[TBL] [Abstract][Full Text] [Related]
14. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
Khan KA; McMurray JL; Mohammed F; Bicknell R
FEBS J; 2019 Sep; 286(17):3299-3332. PubMed ID: 31287944
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.
Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL
PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129
[TBL] [Abstract][Full Text] [Related]
16. CD93 as a Potential Target in Neovascular Age-Related Macular Degeneration.
Tosi GM; Caldi E; Parolini B; Toti P; Neri G; Nardi F; Traversi C; Cevenini G; Marigliani D; Nuti E; Bacci T; Galvagni F; Orlandini M
J Cell Physiol; 2017 Jul; 232(7):1767-1773. PubMed ID: 27859225
[TBL] [Abstract][Full Text] [Related]
17. CD93 maintains endothelial barrier function and limits metastatic dissemination.
Vemuri K; de Alves Pereira B; Fuenzalida P; Subashi Y; Barbera S; van Hooren L; Hedlund M; Pontén F; Lindskog C; Olsson AK; Lugano R; Dimberg A
JCI Insight; 2024 Mar; 9(7):. PubMed ID: 38441970
[TBL] [Abstract][Full Text] [Related]
18. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
[TBL] [Abstract][Full Text] [Related]
19. The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.
Orlandini M; Galvagni F; Bardelli M; Rocchigiani M; Lentucci C; Anselmi F; Zippo A; Bini L; Oliviero S
Oncotarget; 2014 May; 5(9):2750-60. PubMed ID: 24809468
[TBL] [Abstract][Full Text] [Related]
20. CD93 negatively regulates astrogenesis in response to MMRN2 through the transcriptional repressor ZFP503 in the developing brain.
Liang Q; Su L; Zhang D; Jiao J
Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9413-9422. PubMed ID: 32291340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
